Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Y-90, Atezolizumab and Cabozantinib in Advanced HCC
NCT05327738Phase 2Withdrawn
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Dec 2022
- Primary completion
- Dec 2027
- Modality
- Small Molecules, Monoclonal Antibodies
01
Overview
A Phase 2 trial of atezolizumab, cabozantinib in hepatocellular carcinoma (HCC), sponsored by OHSU Knight Cancer Institute. Planned start Dec 2022; status: withdrawn.
02
Drugs
atezolizumabcabozantinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT05327738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05327738.